These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11861386)

  • 1. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.
    Tan C; Waldmann TA
    Cancer Res; 2002 Feb; 62(4):1083-6. PubMed ID: 11861386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
    Satou Y; Nosaka K; Koya Y; Yasunaga JI; Toyokuni S; Matsuoka M
    Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
    Cusack JC; Liu R; Houston M; Abendroth K; Elliott PJ; Adams J; Baldwin AS
    Cancer Res; 2001 May; 61(9):3535-40. PubMed ID: 11325813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
    Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
    Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
    Berenson JR; Ma HM; Vescio R
    Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
    Russo SM; Tepper JE; Baldwin AS; Liu R; Adams J; Elliott P; Cusack JC
    Int J Radiat Oncol Biol Phys; 2001 May; 50(1):183-93. PubMed ID: 11316563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
    Ma MH; Yang HH; Parker K; Manyak S; Friedman JM; Altamirano C; Wu ZQ; Borad MJ; Frantzen M; Roussos E; Neeser J; Mikail A; Adams J; Sjak-Shie N; Vescio RA; Berenson JR
    Clin Cancer Res; 2003 Mar; 9(3):1136-44. PubMed ID: 12631619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
    Sunwoo JB; Chen Z; Dong G; Yeh N; Crowl Bancroft C; Sausville E; Adams J; Elliott P; Van Waes C
    Clin Cancer Res; 2001 May; 7(5):1419-28. PubMed ID: 11350913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
    Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
    Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants.
    Mitra-Kaushik S; Harding JC; Hess JL; Ratner L
    Blood; 2004 Aug; 104(3):802-9. PubMed ID: 15090453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells].
    Satou Y; Matsuoka M
    Nihon Rinsho; 2004 Jul; 62(7):1363-7. PubMed ID: 15283157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
    Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
    Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
    Dai Y; Rahmani M; Grant S
    Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Proteasome inhibitors].
    Hatake K; Mishima Y; Terui Y
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells.
    Abou-Merhi R; Khoriaty R; Arnoult D; El Hajj H; Dbouk H; Munier S; El-Sabban ME; Hermine O; Gessain A; de Thé H; Mahieux R; Bazarbachi A
    Leukemia; 2007 Aug; 21(8):1792-801. PubMed ID: 17568816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
    Amiri KI; Horton LW; LaFleur BJ; Sosman JA; Richmond A
    Cancer Res; 2004 Jul; 64(14):4912-8. PubMed ID: 15256463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition in cancer: development of PS-341.
    Adams J
    Semin Oncol; 2001 Dec; 28(6):613-9. PubMed ID: 11740819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer research. Taking garbage in, tossing cancer out?
    Garber K
    Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical update: proteasome inhibitors in solid tumors.
    Lenz HJ
    Cancer Treat Rev; 2003 May; 29 Suppl 1():41-8. PubMed ID: 12738242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.